[
    {
        "pregunta": "1. How does the quality of evidence (high, moderate, low, very low) impact vaccination recommendations in patients with RMD?",
        "respuesta": "La calidad de la evidencia influye directamente en la fuerza y alcance de las recomendaciones de vacunación en pacientes con enfermedades reumáticas musculoesqueléticas (RMD). Según la información disponible:\n\n- Para pacientes con RMD, se **recomienda condicionalmente** la administración de vacunas no vivas independientemente del grado de actividad de la enfermedad, basándose en evidencia de **muy baja calidad**.  \n- La definición de calidad de evidencia se basa en el sistema GRADE, donde:  \n  - **Muy baja calidad** indica que es muy probable que futuras investigaciones tengan un impacto importante en la confianza y puedan cambiar la estimación del efecto.  \n  - **Baja o moderada calidad** también implican ciertas limitaciones o incertidumbres en la evidencia.  \n\nPor ejemplo, en el caso de la vacunación antigripal en pacientes con RMD con actividad moderada a severa, la calidad de evidencia es considerada **muy baja**, pero aún así se recomienda vacunar sin retrasar la inmunización.\n\nEn resumen, aunque la evidencia para algunas decisiones vacunales en RMD sea de calidad baja o muy baja, las recomendaciones tienden a favorecer la vacunación debido a su importancia, recomendando la inmunización incluso en contextos de actividad activa de la enfermedad, priorizando la prevención sobre la posible incertidumbre en la magnitud del beneficio o riesgo.",
        "contexto": [
            "the efficacy and durability of response to all vaccines across all age groups; 2) safety of primary and booster live attenuated virus vaccination in children taking methotrexate and/or biologic DMARDs; 3) assessment of the immunogenicity, reactogenicity, and disease flares following standard-dose, high-dose, and adjuvanted influenza vaccination, recombinant VZV vaccination, and primary and booster COVID-19 vaccination in RMD patients taking immunosuppressive medication; and 4) RCTs to test the safety and efficacy of holding DMARDs around the time of vaccination.  † The terms 'moderate', 'low', and 'very low' are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) definitions for quality of evidence. Moderate quality means that \"further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.\" Low quality means that \"further research is very likely to have an important impact on our",
            "| <strong>Whether to defer vaccination in patients with high disease activity to maximize vaccine immunogenicity and/or avoid worsening disease activity</strong> | <strong>Very low</strong>                                     | PICO 13. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients who have moderate to severely active underlying disease as compared to those in low disease activity or remission? | 737–739                  |\n| For patients with RMD, giving non–live attenuated vaccinations is conditionally recommended regardless of patients’ disease activity. | <strong>Very low</strong>                                     | PICO 18. Should moderately to severely ill patients with RMD with disease X defer vaccination (not live attenuated) until the disease is better controlled? | 930–931                  |",
            "Rosters of the Core Leadership Team, Literature Review Team, Voting Panel, and Patient Panel are included in Supplementary Appendix 4, available on the Arthritis Care & Research website at http:// onlinelibrary.wiley.com/doi/10.1002/acr.25045 The following guiding principles were used in this guideline: 1) indicated vaccinations should be given to patients whenever possible; 2) this guideline is complementary to recommendations from the ACIP RESULTS/RECOMMENDATIONS Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination For patients with RMD age ≥65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. Any influenza vaccine is preferred over no influenza vaccine, and vaccination \"today\" is preferred over delay. Therefore, if high-dose or adjuvanted",
            "evidence can be found in Table 7 DISCUSSION This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD spectrum. An underlying principle in this guideline is that patients should be vaccinated, and that missed vaccination opportunities should be avoided or minimized. This is particularly true regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the",
            "<p>| <strong>Recommendations</strong>                                                                 | <strong>Level of evidence</strong>                             | <strong>PICO Evidence</strong>                                                                                                   | <strong>Table page numbers</strong>  |\n|-------------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|--------------------------|\n| <strong>Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression</strong> |                                                  |                                                                                                                      |                          |"
        ]
    },
    {
        "pregunta": "2. How should immunosuppressive medications other than methotrexate and rituximab be managed around the time of non-live attenuated vaccine administration?",
        "respuesta": "Los medicamentos inmunosupresores distintos de metotrexato y rituximab se **deben continuar sin suspensión alrededor del momento de la administración de vacunas no vivas atenuadas**. \n\nSegún la guía, para estas vacunas no vivas, se recomienda condicionalmente mantener la medicación inmunosupresora (salvo metotrexato y rituximab, que sí tienen recomendaciones específicas de suspensión o temporización).  \n\nPor lo tanto, no es necesario interrumpir estos otros inmunosupresores para no perder la oportunidad de vacunación ni aumentar el riesgo de actividad de la enfermedad.",
        "contexto": [
            "<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>\n\n<p>| |Influenza vaccination|Other non–live attenuated vaccinations|\n|---|---|---|\n|Methotrexate|Hold methotrexate for 2 weeks after vaccination*|Continue methotrexate|\n|Rituximab|Continue rituximab†|Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination|\n|Immunosuppressive medications other than methotrexate and rituximab|Continue immunosuppressive medication|Continue immunosuppressive medication|</p>\n\n<ul>\n<li>Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</li>\n</ul>",
            "time of influenza vaccination is conditionally recommended. For patients with RMD, continuing immunosuppressive medications around the time of other (non-influenza) nonlive attenuated vaccinations is conditionally recommended. Many observational studies The literature review identified no studies that directly addressed the impact of holding medications other than methotrexate at the time of influenza vaccination. Two RCTs performed in patients initiating TNFi versus placebo demonstrated similar responses to influenza vaccination in the 2 arms Rituximab For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due. For patients with RMD receiving rituximab, deferring non-live attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is",
            "other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended. Influenza vaccine responses are greater when the vaccine is administered later rather than earlier after rituximab Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or with active disease (Table 4 Glucocorticoids Whether to administer non-live attenuated vaccinations to patients taking glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity. For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non-live vaccinations is strongly recommended. For patients with RMD who are taking the equivalent of prednisone >10 mg daily but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering",
            "For RMD patients who are on immunosuppressive medication, deferring live-attenuated vaccines is conditionally recommended. For RMD patients, holding immunosuppressive medication for an appropriate period before (see JAK= Janus kinase; TNF=tumor necrosis factor; IL=interleukin; IVIG= intravenous immunoglobulin G; IV = intravenous a for patients taking the equivalent of prednisone < 20 mg/day or < 2 mg/kg/day for patients weighing < 10 kg, or alternate-day glucocorticoid therapy (i.e., \"low level immunosuppression\" (14, 68), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency off glucocorticoids is high. b for patients taking methotrexate ≤ 0.4 mg/kg/week or azathioprine ≤ 3 mg/kg/day (\"low level\" immunosuppression\" (14, 68), hold times can be shortened if vaccination is critical and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest",
            "and the Voting Panel conditionally recommended against administering live attenuated virus vaccines to patients receiving those agents as well as other forms of immunosuppression. For patients who do need to receive live attenuated vaccines, specific recommendations for holding immunosuppressive medications around the time of vaccination can be found in Table 5 For slow-acting conventional DMARDs, a prevaccination hold time of 4 weeks was chosen to reflect their prolonged duration of action. However, direct evidence for the optimal hold time is lacking. For most biologic DMARDs, a hold time of 1 dosing interval before live attenuated vaccine administration is recommended. The number of RMD patients who are taking immunosuppressive medications at the time that they need live attenuated virus vaccines is small. However, very young children, especially those with autoinflammatory disorders, may require biologic DMARDs before their primary vaccination series is complete. In these"
        ]
    },
    {
        "pregunta": "3. What is the rationale for holding IVIG prior to vaccination?",
        "respuesta": "La justificación para suspender la administración de inmunoglobulina intravenosa (IVIG) antes de la vacunación es **para mejorar la eficacia de la vacuna**, no por razones de seguridad. En algunas situaciones especiales, como durante un brote de sarampión, se prefiere administrar la vacuna antes de retrasar la vacunación para no perder la oportunidad de inmunización.",
        "contexto": [
            "<p>§ For medications with &gt;1 dosing interval approved by the Food and Drug Administration, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks, although it can be dosed every 1 or every 2 weeks).</p>\n\n<p>¶ In children with autoinﬂammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic disease-modifying antirheumatic drugs are held is very high, shorter hold times can be considered if live attenuated vaccination is critical.</p>\n\n<h1>The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efﬁcacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</h1>\n\n<h1>Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*</h1>",
            "and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks). d In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero",
            "<p>d. In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical.</p>\n\n<p>e. the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</p>\n\n<h1>When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero</h1>\n\n<p>|Antenatal drug exposure in second or third trimester|Within the first 6 months of life|After 6 months of life|\n|---|---|---|\n|TNF inhibitor|Give rotavirus vaccine| |\n|Rituximab|Do not give rotavirus vaccine|Give rotavirus vaccine|</p>",
            "<p>JAK= Janus kinase; TNF=tumor necrosis factor; IL=interleukin; IVIG= intravenous immunoglobulin G; IV = intravenous</p>\n\n<p>a. for patients taking the equivalent of prednisone &lt; 20 mg/day or &lt; 2 mg/kg/day for patients weighing &lt; 10 kg, or alternate-day glucocorticoid therapy (i.e., “low level immunosuppression” (14, 68), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency off glucocorticoids is high.</p>\n\n<p>b. for patients taking methotrexate ≤ 0.4 mg/kg/week or azathioprine ≤ 3 mg/kg/day (“low level” immunosuppression” (14, 68), hold times can be shortened if vaccination is critical and the risk of a disease flare off immunosuppression is high.</p>\n\n<p>c. for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks).</p>",
            "For RMD patients who are on immunosuppressive medication, deferring live-attenuated vaccines is conditionally recommended. For RMD patients, holding immunosuppressive medication for an appropriate period before (see JAK= Janus kinase; TNF=tumor necrosis factor; IL=interleukin; IVIG= intravenous immunoglobulin G; IV = intravenous a for patients taking the equivalent of prednisone < 20 mg/day or < 2 mg/kg/day for patients weighing < 10 kg, or alternate-day glucocorticoid therapy (i.e., \"low level immunosuppression\" (14, 68), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency off glucocorticoids is high. b for patients taking methotrexate ≤ 0.4 mg/kg/week or azathioprine ≤ 3 mg/kg/day (\"low level\" immunosuppression\" (14, 68), hold times can be shortened if vaccination is critical and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest"
        ]
    },
    {
        "pregunta": "4. What is the evidence quality regarding holding immunosuppressive medications to improve vaccine response?",
        "respuesta": "La calidad de la evidencia respecto a la suspensión (holding) de medicamentos inmunosupresores para mejorar la respuesta a la vacunación en pacientes con enfermedades reumáticas musculoesqueléticas (RMD) es en general **muy baja para la mayoría de las comparaciones**, aunque hay evidencia de calidad **moderada en algunos pocos casos**, como con metotrexato y tofacitinib, pero solo evidencia indirecta para otros inmunosupresores.\n\nEsto significa que:\n\n- Hay poca evidencia sólida que respalde suspendar los inmunosupresores alrededor del momento de la vacunación para mejorar la respuesta inmunitaria, salvo algunas excepciones.  \n- Por lo tanto, la recomendación es **condicional a favor de continuar la mayoría de medicamentos inmunosupresores (excepto metotrexato y rituximab, que sí tienen recomendaciones específicas sobre su manejo)** al recibir vacunas no vivas atenuadas, para evitar el riesgo de brotes o pérdida del control de la enfermedad.  \n- Futuros estudios probablemente impactarán esta estimación debido a la baja calidad actual de la evidencia.\n\nEn resumen, la evidencia actual es de **muy baja calidad para la mayoría de inmunosupresores**, limitando la fuerza de las recomendaciones sobre la suspensión de medicación para mejorar la respuesta vacunal en pacientes con RMD.",
        "contexto": [
            "the efficacy and durability of response to all vaccines across all age groups; 2) safety of primary and booster live attenuated virus vaccination in children taking methotrexate and/or biologic DMARDs; 3) assessment of the immunogenicity, reactogenicity, and disease flares following standard-dose, high-dose, and adjuvanted influenza vaccination, recombinant VZV vaccination, and primary and booster COVID-19 vaccination in RMD patients taking immunosuppressive medication; and 4) RCTs to test the safety and efficacy of holding DMARDs around the time of vaccination.  † The terms 'moderate', 'low', and 'very low' are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) definitions for quality of evidence. Moderate quality means that \"further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.\" Low quality means that \"further research is very likely to have an important impact on our",
            "| <strong>PICO 16</strong>                                                                           | <strong>MTX: moderate; tofacitinib: low; other medications: indirect evidence only</strong> | PICO 16. Should patients with RMD taking drug Y hold their drug Y for a period of time prior to or after receiving (not live attenuated) vaccines? | 898–927                  |\n| <strong>For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |",
            "<p>| <strong>Recommendations</strong>                                                                 | <strong>Level of evidence</strong>                             | <strong>PICO Evidence</strong>                                                                                                   | <strong>Table page numbers</strong>  |\n|-------------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|--------------------------|\n| <strong>Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression</strong> |                                                  |                                                                                                                      |                          |",
            "| <strong>For patients with RMD, continuing immunosuppressive medications around the time of other (non‐influenza) non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |\n| <strong>Timing vaccinations in patients receiving rituximab to maximize vaccine efficacy</strong>    | <strong>Low</strong>                                          | PICO 17. Should patients with RMD who are taking rituximab time non–live attenuated vaccine administration relative to the next dose of medication? | 927–930                  |",
            "evidence can be found in Table 7 DISCUSSION This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD spectrum. An underlying principle in this guideline is that patients should be vaccinated, and that missed vaccination opportunities should be avoided or minimized. This is particularly true regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the"
        ]
    },
    {
        "pregunta": "5. In children with systemic juvenile idiopathic arthritis, when can shorter hold times for biologic DMARDs be considered?",
        "respuesta": "En niños con artritis idiopática juvenil sistémica (AIJ sistémica) cuya enfermedad esté inactiva, la guía indica que se **puede considerar la suspensión o reducción de dosis de los fármacos biológicos modificadores de la enfermedad (biológicos DMARDs) de forma condicional**, es decir, de manera cuidadosa y adaptada al caso, una vez que se ha logrado el estado de enfermedad inactiva.\n\nNo obstante, los tiempos de suspensión más cortos o específicos no se describen con precisión en la información proporcionada. La recomendación enfatiza que la suspensión o reducción debe evaluarse según la estabilidad clínica, dado que conservar la inactividad de la enfermedad es prioritario.\n\nEn resumen:\n\n- La suspensión o tapering de biológicos DMARDs en AIJ sistémica se recomienda condicionalmente tras la consecución de enfermedad inactiva.  \n- No se especifican tiempos concretos ni criterios precisos para hacer esta suspensión más corta o rápida.  \n- La decisión debe individualizarse para mantener la inactividad y minimizar riesgos.\n\nPor lo tanto, no hay información suficiente para definir inequívocamente cuándo se pueden considerar tiempos de suspensión más cortos para los biológicos en esta población.",
        "contexto": [
            "should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|\n|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at low doses Tapering and discontinuing bDMARDs is conditionally recommended after inactive disease has been attained in systemic JIA. In children with systemic JIA whose disease is inactive, it may be possible to maintain this inactive disease state with lower doses of, or discontinuation of, bDMARDs 86 DISCUSSION The recommendations presented herein are a companion to those published in 2019 The Voting Panel and",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|</p>",
            "switching among and between IL-1 and IL-6 inhibitors when needed due to lack of efficacy or poor tolerability is appropriate. Concerns were expressed regarding a highly fatal lung disease observed in some children with systemic JIA, most of whom were treated with bDMARDs. Observed risk factors include younger age with MAS, a history of reactions to tocilizumab, and trisomy 21 NSAIDs NSAIDs are conditionally recommended as initial monotherapy for systemic JIA without MAS. Studies suggest that a small proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately"
        ]
    },
    {
        "pregunta": "6. What are tsDMARDs and which vaccines are considered safe or not safe to administer in patients treated with these drugs?",
        "respuesta": "Los **tsDMARDs** (medicamentos modificadores de la enfermedad dirigidos por vías intrínsecas) incluyen inhibidores de JAK como tofacitinib, baricitinib, upadacitinib, filgotinib y ruxolitinib.\n\nRespecto a la vacunación en pacientes tratados con tsDMARDs:\n\n- Se consideran **seguras para administrar las vacunas no vivas**, tales como:  \n  - Vacuna contra la influenza estacional (inactivada)  \n  - PPSV23 (vacuna neumocócica polisacárida)  \n  - PCV13 (vacuna neumocócica conjugada)  \n  - Vacunas contra Haemophilus influenzae tipo b  \n  - Hepatitis A y B  \n  - Virus del papiloma humano  \n  - Polio inactivada  \n  - Meningococo B y ACWY  \n  - Vacunas toxoides tetánicos (Tdap)  \n  - Vacuna antitifoidea inyectable  \n  - Vacuna zóster subunidade (vacuna zóster no viva)\n\n- Se consideran **no seguras o contraindicadas las vacunas vivas** o atenuadas en estos pacientes, que incluyen:  \n  - Vacuna contra influenza intranasal (vivaisimada)  \n  - MMR (sarampión, paperas y rubéola)  \n  - Rotavirus  \n  - Vacuna antitifoidea oral  \n  - Varicela  \n  - Vacuna zóster viva  \n  - Vacuna de la fiebre amarilla\n\nEn resumen, en pacientes bajo tratamiento con tsDMARDs se recomienda administrar exclusivamente vacunas no vivas; las vacunas vivas se consideran contraindicadas debido al riesgo de enfermedad por la vacuna en inmunosuprimidos.",
        "contexto": [
            "| tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib).                                                                               |\n| Triple therapy refers to hydroxychloroquine, sulfasalazine, and either methotrexate or leflunomide.                                              |\n| Serious infection refers to an infection requiring intravenous antibiotics or hospitalization.                                                  |\n| Biosimilars are considered equivalent to FDA-approved originator bDMARDs.                                                                      |\n| Recommendations referring to bDMARDs exclude rituximab unless patients have had an inadequate response to TNF inhibitors (in order to be consistent with FDA approval) or have a history of lymphoproliferative disorder for which rituximab is an approved therapy. |",
            "of very low-certainty evidence favoring bDMARDs or tsDMARDs, randomized controlled trials demonstrating equivalent long-term outcomes across both treatment strategies, and significantly less societal cost associated with triple therapy 1 Switching to a bDMARD or tsDMARD of a different class is conditionally recommended over switching to a bDMARD or tsDMARD belonging to the same class for patients taking a bDMARD or tsDMARD who are not at target The recommendation is based on very low-certainty evidence supporting greater improvement in disease activity and drug survival among patients switching classes. The recommendation is conditional because patient and physician preferences are likely to vary based on prior experiences with specific DMARDs. Use of glucocorticoids Addition of/switching to DMARDs is conditionally recommended over continuation of glucocorticoids for patients taking glucocorticoids to remain at target This recommendation assumes that improved disease control with",
            "<p>| <strong>Questions</strong>                                                                                                                                                                  |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| At what dose and route of administration should methotrexate be started?                                                                                                        |\n| Does switching to non-methotrexate DMARDs improve tolerability over increasing the dose of folic acid, or using folinic acid or using split dose or subcutaneous dosing, for RA patients with side effects when taking methotrexate? |\n| What is the efficacy of TTT in different patient populations (early versus late, bDMARD-or tsDMARD-exposed, elderly-onset, comorbidities)?                                      |",
            "| <strong>tsDMARDs</strong>: JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, ruxolitinib), Denosumab, IVIG                                                                | <strong>Apremilast</strong>                                                                                                     | <strong>Seasonal influenza</strong><br><strong>PPSV23, PCV13</strong><br><strong>Hemophilus influenza b</strong><br><strong>Hepatitis A</strong><br><strong>Hepatitis B</strong><br><strong>Human papillomavirus</strong><br><strong>Inactivated polio</strong><br><strong>Meningococcus B</strong><br><strong>Meningococcus ACWY</strong><br><strong>Tetanus toxoid/Td/Tdap</strong><br><strong>Typhoid (injectable)</strong><br><strong>Zoster subunit</strong> | <strong>Influenza (intranasal)</strong><br><strong>MMR</strong><br><strong>Rotavirus</strong><br><strong>Typhoid (oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> |",
            "| <strong>csDMARDs</strong>: Methotrexate, Leflunomide, Azathioprine, Mycophenolate mofetil/mycophenolic acid, Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin), Cyclophosphamide | <strong>Sulfasalazine</strong>                                                                                                    | <strong>PPSV23, PCV13</strong><br><strong>Hemophilus influenza b</strong><br><strong>Hepatitis A</strong><br><strong>Hepatitis B</strong><br><strong>Human papillomavirus</strong><br><strong>Inactivated polio</strong><br><strong>Meningococcus B</strong><br><strong>Meningococcus ACWY</strong><br><strong>Tetanus toxoid/Td/Tdap</strong><br><strong>Typhoid (injectable)</strong><br><strong>Zoster subunit</strong> | <strong>Influenza (intranasal)</strong><br><strong>MMR</strong><br><strong>Rotavirus</strong><br><strong>Typhoid (oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Systemic lupus"
        ]
    },
    {
        "pregunta": "7. What are the general recommendations regarding the use of high-dose or adjuvanted influenza vaccines in patients with RMD?",
        "respuesta": "Las recomendaciones generales sobre el uso de vacunas antigripales de alta dosis o adyuvadas en pacientes con enfermedades reumáticas musculoesqueléticas (RMD) son las siguientes:\n\n- Para pacientes con RMD **de 65 años o más**, y también para aquellos con RMD entre **18 y 65 años que estén recibiendo medicación inmunosupresora**, se **recomienda condicionalmente el uso de vacunas antigripales de alta dosis o adyuvadas en lugar de las dosis regulares**.  \n\n- Esta recomendación se basa en la preferencia por una mejor protección inmunológica frente a la influenza en estos grupos con mayor riesgo o con compromiso del sistema inmunitario.  \n\n- Además, se destaca que cualquier vacuna antigripal es preferible a no vacunarse y que la vacunación debe realizarse con la mayor prontitud posible (“vacunarse hoy”), sin retrasos.\n\nEn resumen, en pacientes con RMD en riesgo aumentado por edad o uso de inmunosupresores, se favorece el uso de vacunas antigripales de alta dosis o adyuvadas para optimizar la respuesta inmunitaria, siempre considerando la vacunación inmediata.",
        "contexto": [
            "2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases      D064A5AD64D848FEC553AA8136BD6112 10.1002/acr.25045  Conclusion: Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended. For patients with RMD aged >18 years who are",
            "Rosters of the Core Leadership Team, Literature Review Team, Voting Panel, and Patient Panel are included in Supplementary Appendix 4, available on the Arthritis Care & Research website at http:// onlinelibrary.wiley.com/doi/10.1002/acr.25045 The following guiding principles were used in this guideline: 1) indicated vaccinations should be given to patients whenever possible; 2) this guideline is complementary to recommendations from the ACIP RESULTS/RECOMMENDATIONS Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination For patients with RMD age ≥65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. Any influenza vaccine is preferred over no influenza vaccine, and vaccination \"today\" is preferred over delay. Therefore, if high-dose or adjuvanted",
            "2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases  American College of Rheumatology      263B6488AC287683F9490992215EE324 10.1002/acr.25045 Submitted for publication August 8, 2022; accepted in revised form October 13, 2022.  INTRODUCTION Rheumatic and musculoskeletal diseases (RMDs) 1 2 Avacopan and bimekizumab, the pneumococcal vaccines PCV15 and PCV20, and the smallpox/monkeypox vaccine were not included in the formal evidence review because they were not approved at the time of the project plan. Antipyretic medications such as nonsteroidal antiinflammatory drugs and acetaminophen were also not included. Although a few randomized controlled trials (RCTs) have demonstrated blunted antibody responses with antipyretics, this was seen after primary vaccination only, and not after booster The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination",
            "evidence can be found in Table 7 DISCUSSION This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD spectrum. An underlying principle in this guideline is that patients should be vaccinated, and that missed vaccination opportunities should be avoided or minimized. This is particularly true regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the",
            "and not after booster The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination should be administered to all RMD patients taking immunosuppressive medication; 2) recombinant zoster vaccination is recommended for RMD patients >18 years of age taking immunosuppressive medication; 3) methotrexate should be held for 2 weeks after influenza vaccination if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology. org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines Voting Panel consensus required"
        ]
    },
    {
        "pregunta": "8. Under what circumstances should seasonal influenza vaccination be administered to RMD patients, even if disease activity is high or patients are on high-dose glucocorticoids or rituximab?",
        "respuesta": "La vacunación antigripal estacional debe administrarse a pacientes con enfermedades reumáticas musculoesqueléticas (RMD) **incluso cuando la actividad de la enfermedad sea alta, estén recibiendo glucocorticoides en dosis elevadas y/o tratamiento con rituximab**. \n\nEsta recomendación se basa en la evidencia disponible y refleja la preferencia de la guía por vacunar sin demora para prevenir infecciones prevenibles, priorizando la protección del paciente aun en condiciones de mayor actividad inflamatoria o inmunosupresión.  \n\nEn resumen:  \n- **Se recomienda administrar la vacuna antigripal en todo paciente con RMD.**  \n- **No se debe retrasar la vacunación por alta actividad de la enfermedad, dosis altas de glucocorticoides o tratamiento con rituximab.**  \n- La vacuna antigripal estacional es preferible a no vacunar, considerando siempre una evaluación clínica individualizada.",
        "contexto": [
            "evidence can be found in Table 7 DISCUSSION This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD spectrum. An underlying principle in this guideline is that patients should be vaccinated, and that missed vaccination opportunities should be avoided or minimized. This is particularly true regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the",
            "and not after booster The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination should be administered to all RMD patients taking immunosuppressive medication; 2) recombinant zoster vaccination is recommended for RMD patients >18 years of age taking immunosuppressive medication; 3) methotrexate should be held for 2 weeks after influenza vaccination if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology. org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines Voting Panel consensus required",
            "2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases      D064A5AD64D848FEC553AA8136BD6112 10.1002/acr.25045  Conclusion: Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended. For patients with RMD aged >18 years who are",
            "Rosters of the Core Leadership Team, Literature Review Team, Voting Panel, and Patient Panel are included in Supplementary Appendix 4, available on the Arthritis Care & Research website at http:// onlinelibrary.wiley.com/doi/10.1002/acr.25045 The following guiding principles were used in this guideline: 1) indicated vaccinations should be given to patients whenever possible; 2) this guideline is complementary to recommendations from the ACIP RESULTS/RECOMMENDATIONS Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination For patients with RMD age ≥65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. Any influenza vaccine is preferred over no influenza vaccine, and vaccination \"today\" is preferred over delay. Therefore, if high-dose or adjuvanted",
            "| For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. |                                                  |                                                                                                                      |                          |\n| <strong>PICO 15</strong>                                                                           | <strong>TNFi: low; tocilizumab: very low; secukinumab: very low; tofacitinib: moderate; glucocorticoids: very low; abatacept: very low</strong> | PICO 15. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking drug Y as compared to those not taking drug Y at the time of vaccination? | 754–898                  |"
        ]
    },
    {
        "pregunta": "9. Why might non-rheumatology providers be encouraged to administer influenza vaccination even if methotrexate is not held immediately?",
        "respuesta": "Se podría estimular a los proveedores no reumatológicos a administrar la vacuna antigripal incluso si no se suspende inmediatamente el metotrexato porque la suspensión de metotrexato debe realizarse solo si la actividad de la enfermedad lo permite, y no hacerlo no debe impedir la vacunación. Esto evita perder la oportunidad de inmunizar al paciente. Luego, el reumatólogo puede ser consultado para valorar la conveniencia de suspender metotrexato por dos semanas después de la vacunación para optimizar la respuesta inmunitaria.  \n\nEn resumen: se prioriza la administración oportuna de la vacuna antigripal, y la suspensión de metotrexato se maneja de manera coordinada para no demorar ni impedir la inmunización.",
        "contexto": [
            "| For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. |                                                  |                                                                                                                      |                          |\n| <strong>PICO 15</strong>                                                                           | <strong>TNFi: low; tocilizumab: very low; secukinumab: very low; tofacitinib: moderate; glucocorticoids: very low; abatacept: very low</strong> | PICO 15. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking drug Y as compared to those not taking drug Y at the time of vaccination? | 754–898                  |",
            "<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>\n\n<p>| |Influenza vaccination|Other non–live attenuated vaccinations|\n|---|---|---|\n|Methotrexate|Hold methotrexate for 2 weeks after vaccination*|Continue methotrexate|\n|Rituximab|Continue rituximab†|Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination|\n|Immunosuppressive medications other than methotrexate and rituximab|Continue immunosuppressive medication|Continue immunosuppressive medication|</p>\n\n<ul>\n<li>Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</li>\n</ul>",
            "other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended. Influenza vaccine responses are greater when the vaccine is administered later rather than earlier after rituximab Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or with active disease (Table 4 Glucocorticoids Whether to administer non-live attenuated vaccinations to patients taking glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity. For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non-live vaccinations is strongly recommended. For patients with RMD who are taking the equivalent of prednisone >10 mg daily but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering",
            "as well as patient and clinician preferences. The voting panel cautioned that many patients treated with certain monoclonal antibodies may require ongoing treatment with methotrexate to prevent the formation of antidrug antibodies Recommendations for specific patient populations (Table 6) Subcutaneous nodules Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-tohigh disease activity Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules While accelerated nodulosis has been observed in patients starting methotrexate Pulmonary disease Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high",
            "time of influenza vaccination is conditionally recommended. For patients with RMD, continuing immunosuppressive medications around the time of other (non-influenza) nonlive attenuated vaccinations is conditionally recommended. Many observational studies The literature review identified no studies that directly addressed the impact of holding medications other than methotrexate at the time of influenza vaccination. Two RCTs performed in patients initiating TNFi versus placebo demonstrated similar responses to influenza vaccination in the 2 arms Rituximab For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due. For patients with RMD receiving rituximab, deferring non-live attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is"
        ]
    },
    {
        "pregunta": "10. What are the vaccination recommendations for patients with RMD taking prednisone at doses ≤10 mg daily?",
        "respuesta": "Para pacientes con enfermedades reumáticas musculoesqueléticas (RMD) que están tomando prednisona en dosis **≤10 mg diarios**, las recomendaciones de vacunación basadas en la guía disponible son las siguientes:\n\n- Se **recomienda la administración de vacunas no vivas atenuadas** sin necesidad de posponer por el uso de dosis bajas de glucocorticoides (≤10 mg/día).  \n- La inmunogenicidad y eficacia de las vacunas, incluyendo la vacuna antigripal, no se ven significativamente afectadas a estas dosis bajas de prednisona, en contraste con dosis más altas (≥20 mg/día), por lo que no se requiere diferir las vacunaciones.  \n- En general, la vacunación debe realizarse oportunamente, priorizando la prevención de enfermedades prevenibles y evitando retrasos innecesarios.\n\nEn resumen, en pacientes con RMD bajo tratamiento con prednisona a dosis iguales o menores de 10 mg diarios, la vacunación debe realizarse sin modificaciones especiales en el esquema debido al tratamiento con glucocorticoides, ya que el riesgo de baja respuesta inmune es menor y el beneficio esperado es alto.",
        "contexto": [
            "2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases      D064A5AD64D848FEC553AA8136BD6112 10.1002/acr.25045  Conclusion: Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended. For patients with RMD aged >18 years who are",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non–live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579                  |",
            "non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally recommended. Most studies that have compared prednisone <10 mg daily to prednisone ≥10 mg daily found that the higher dosages did reduce influenza vaccine immunogenicity Given the importance of timely influenza vaccination, a conditional recommendation was made to administer influenza vaccination to patients receiving the equivalent of prednisone ≥20 mg daily. For vaccines other than for influenza, a conditional recommendation was made to delay vaccination until the dose is lower to maximize vaccine efficacy. It is understood, however,",
            "| <strong>For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "Rosters of the Core Leadership Team, Literature Review Team, Voting Panel, and Patient Panel are included in Supplementary Appendix 4, available on the Arthritis Care & Research website at http:// onlinelibrary.wiley.com/doi/10.1002/acr.25045 The following guiding principles were used in this guideline: 1) indicated vaccinations should be given to patients whenever possible; 2) this guideline is complementary to recommendations from the ACIP RESULTS/RECOMMENDATIONS Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination For patients with RMD age ≥65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. Any influenza vaccine is preferred over no influenza vaccine, and vaccination \"today\" is preferred over delay. Therefore, if high-dose or adjuvanted"
        ]
    },
    {
        "pregunta": "11. How should methotrexate dosing be managed around the time of vaccination?",
        "respuesta": "La recomendación sobre la suspensión o ajuste de la dosis de metotrexato en relación con la administración de vacunas es la siguiente:\n\n- **Para la vacuna antigripal (influenza) no viva:** se **condiciona suspender metotrexato durante 2 semanas después de la vacunación**, siempre que la actividad de la enfermedad lo permita.  \n- **Para otras vacunas no vivas atenuadas:** se recomienda **continuar metotrexato sin suspensión**.\n\nAdemás, se alienta a que los proveedores no reumatológicos administren la vacuna antigripal aunque inicialmente no se suspenda metotrexato, para no perder la oportunidad de vacunar, y luego consultar con el reumatólogo sobre la suspensión del medicamento. \n\nEn resumen, la suspensión de metotrexato es especialmente recomendada por 2 semanas posvacunación solo para la vacuna antigripal, mientras que para otras vacunas no vivas se mantiene el tratamiento sin cambios.",
        "contexto": [
            "<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>\n\n<p>| |Influenza vaccination|Other non–live attenuated vaccinations|\n|---|---|---|\n|Methotrexate|Hold methotrexate for 2 weeks after vaccination*|Continue methotrexate|\n|Rituximab|Continue rituximab†|Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination|\n|Immunosuppressive medications other than methotrexate and rituximab|Continue immunosuppressive medication|Continue immunosuppressive medication|</p>\n\n<ul>\n<li>Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</li>\n</ul>",
            "| For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. |                                                  |                                                                                                                      |                          |\n| <strong>PICO 15</strong>                                                                           | <strong>TNFi: low; tocilizumab: very low; secukinumab: very low; tofacitinib: moderate; glucocorticoids: very low; abatacept: very low</strong> | PICO 15. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking drug Y as compared to those not taking drug Y at the time of vaccination? | 754–898                  |",
            "<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Methotrexate|Hold methotrexate for 2 weeks after vaccination<em>|Continue methotrexate|\n|Rituximab|Continue rituximab</em>*|Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination|\n|Immunosuppressive medications other than methotrexate and rituximab|Continue immunosuppressive medication|Continue immunosuppressive medication|</p>\n\n<p>*Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</p>\n\n<p>**Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>\n\n<p>**Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt; 20 mg daily.</p>\n\n<p>++ Strong Recommendation</p>\n\n<ul>\n<li>Conditional recommendation</li>\n</ul>\n\n<h1>Table 3. Immunosuppressive medication management at the time of live-attenuated virus vaccine administration</h1>",
            "<p>++ = Strong recommendation.</p>\n\n<ul>\n<li><p>= Conditional recommendation.</p></li>\n<li><p>Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p></li>\n</ul>\n\n<p>† Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily.</p>\n\n<h1>Table 5. Immunosuppressive medication management at the time of live attenuated virus vaccine administration*</h1>"
        ]
    },
    {
        "pregunta": "12. What vaccines are classified as non-live attenuated vaccines suitable for patients on immunosuppressive therapy?",
        "respuesta": "Las vacunas clasificadas como **no vivas atenuadas** y adecuadas para pacientes con enfermedades reumáticas musculoesqueléticas (RMD) en tratamiento con inmunosupresores, según la información proporcionada, incluyen las siguientes:\n\n- Vacuna contra la influenza estacional (inactivada, no intranasal)  \n- PPSV23 (vacuna neumocócica polisacárida)  \n- PCV13 (vacuna neumocócica conjugada)  \n- Vacuna contra Haemophilus influenzae tipo b  \n- Vacunas contra hepatitis A y hepatitis B  \n- Vacuna contra el virus del papiloma humano (VPH)  \n- Vacuna antipolio inactivada  \n- Vacunas meningocócicas B y ACWY  \n- Vacuna toxoide tetánico (Tdap)  \n- Vacuna antitifoidea inyectable  \n- Vacuna zóster subunidad (no viva)\n\nEstas vacunas pueden administrarse de manera condicional manteniendo la medicación inmunosupresora (excepto recomendaciones específicas para metotrexato y rituximab), y son consideradas seguras y recomendadas para pacientes con RMD bajo inmunosupresión.\n\nPor el contrario, las vacunas **vivales atenuadas** no se recomiendan en pacientes bajo inmunosupresión y incluyen:\n\n- Vacuna influenza intranasal (vacuna viva atenuada)  \n- MMR (sarampión, paperas y rubéola)  \n- Rotavirus  \n- Vacuna antitifoidea oral  \n- Varicela  \n- Vacuna zóster viva  \n- Vacuna de fiebre amarilla\n\nEn resumen, para pacientes en tratamiento con inmunosupresores se deben utilizar preferentemente las vacunas no vivas atenuadas listadas arriba, evitando las vacunas vivas debido al riesgo potencial para esta población.",
        "contexto": [
            "<p>| <strong>Immunosuppressive</strong>                                                                                                       | <strong>Non-Immunosuppressive</strong>                                                                                            | <strong>Non-live attenuated</strong>                                                                                                                                                                                                                  | <strong>Live attenuated</strong>                                                                                                                                                                  | <strong>Rheumatic and Musculoskeletal Disorders</strong>                                                 |",
            "| <strong>For patients with RMD, continuing immunosuppressive medications around the time of other (non‐influenza) non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |\n| <strong>Timing vaccinations in patients receiving rituximab to maximize vaccine efficacy</strong>    | <strong>Low</strong>                                          | PICO 17. Should patients with RMD who are taking rituximab time non–live attenuated vaccine administration relative to the next dose of medication? | 927–930                  |",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>\n\n<p>**Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt; 20 mg daily.</p>\n\n<p>++ Strong Recommendation</p>\n\n<ul>\n<li>Conditional recommendation</li>\n</ul>\n\n<h1>Table 3. Immunosuppressive medication management at the time of live-attenuated virus vaccine administration</h1>",
            "| <strong>csDMARDs</strong>: Methotrexate, Leflunomide, Azathioprine, Mycophenolate mofetil/mycophenolic acid, Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin), Cyclophosphamide | <strong>Sulfasalazine</strong>                                                                                                    | <strong>PPSV23, PCV13</strong><br><strong>Hemophilus influenza b</strong><br><strong>Hepatitis A</strong><br><strong>Hepatitis B</strong><br><strong>Human papillomavirus</strong><br><strong>Inactivated polio</strong><br><strong>Meningococcus B</strong><br><strong>Meningococcus ACWY</strong><br><strong>Tetanus toxoid/Td/Tdap</strong><br><strong>Typhoid (injectable)</strong><br><strong>Zoster subunit</strong> | <strong>Influenza (intranasal)</strong><br><strong>MMR</strong><br><strong>Rotavirus</strong><br><strong>Typhoid (oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Systemic lupus",
            "<p>† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>\n\n<h1>Table 4. Whether to give or defer non–live attenuated vaccinations that can be safely given to RMD patients taking immunosuppressive medication.</h1>\n\n<p>|                               | <strong>Influenza vaccination</strong>    | <strong>Other non–live attenuated vaccinations</strong> |\n|-------------------------------|------------------------------|--------------------------------------------|\n| <strong>Prednisone ≤10 mg daily<em></strong>   | ++ Give                         |  ++Give                                       |\n| <strong>Prednisone &gt;10 mg and &lt;20 mg</em></strong> | + Give                         | + Give                                       |\n| <strong>Prednisone ≥20 mg daily*</strong>   | + Give                         | + Defer†                                     |</p>"
        ]
    },
    {
        "pregunta": "13. What is the conditional recommendation for influenza vaccination in patients taking prednisone ≥20 mg daily?",
        "respuesta": "La recomendación condicional respecto a la vacunación antigripal en pacientes con enfermedades reumáticas musculoesqueléticas que toman prednisona en dosis **≥20 mg diarios** es **administrar la vacuna antigripal sin retraso**, a pesar de la dosis elevada de glucocorticoides. Esto se fundamenta en la importancia de vacunar oportunamente para prevenir la infección, aunque la inmunogenicidad pueda estar reducida a estas dosis altas.\n\nEn resumen:\n- Para prednisona ≥20 mg/día:  \n  **Vacunación antigripal recomendada condicionalmente sin diferir el esquema.**\n\nEsta recomendación refleja que, aunque las dosis altas de glucocorticoides pueden reducir la respuesta inmunitaria, el beneficio de la vacunación precoz supera este riesgo y se prioriza la protección frente a la influenza.",
        "contexto": [
            "non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally recommended. Most studies that have compared prednisone <10 mg daily to prednisone ≥10 mg daily found that the higher dosages did reduce influenza vaccine immunogenicity Given the importance of timely influenza vaccination, a conditional recommendation was made to administer influenza vaccination to patients receiving the equivalent of prednisone ≥20 mg daily. For vaccines other than for influenza, a conditional recommendation was made to delay vaccination until the dose is lower to maximize vaccine efficacy. It is understood, however,",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>\n\n<p>**Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt; 20 mg daily.</p>\n\n<p>++ Strong Recommendation</p>\n\n<ul>\n<li>Conditional recommendation</li>\n</ul>\n\n<h1>Table 3. Immunosuppressive medication management at the time of live-attenuated virus vaccine administration</h1>",
            "| <strong>For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non–live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579                  |",
            "<p>++ = Strong recommendation.</p>\n\n<ul>\n<li><p>= Conditional recommendation.</p></li>\n<li><p>Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p></li>\n</ul>\n\n<p>† Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily.</p>\n\n<h1>Table 5. Immunosuppressive medication management at the time of live attenuated virus vaccine administration*</h1>"
        ]
    },
    {
        "pregunta": "14. In what way can intravenous immunoglobulin (IVIG) therapy impact the efficacy of live attenuated vaccines?",
        "respuesta": "La terapia con inmunoglobulina intravenosa (IVIG) puede **disminuir la eficacia de las vacunas vivas atenuadas** porque los anticuerpos antivirales que contiene pueden interferir con la replicación del virus atenuado de la vacuna.  \n\nPor esta razón, se recomienda **suspender IVIG antes de la vacunación** para mejorar la eficacia inmunitaria de la vacuna, no por razones de seguridad.  \n\nEs importante destacar que, en situaciones especiales (por ejemplo, durante un brote de sarampión), puede ser preferible administrar la vacuna sin demora antes que retrasarla por la administración de IVIG.",
        "contexto": [
            "patients developed vaccine-associated infection, and 7 of 17 patients experienced disease flares JAK inhibitors. Cutaneous vaccine-strain varicella infection developed in 1 of 55 RA patients given a single dose of the live attenuated VZV vaccine 2-3 weeks prior to tofacitinib initiation in the context of an RCT. Later testing demonstrated that the study participant lacked prevaccination immunity to VZV Intravenous immunoglobulin (IVIG). Antiviral antibodies contained in IVIG can interfere with replication of live attenuated vaccines and reduce their efficacy Specific recommendations for holding medications if live attenuated vaccines are given. Although the evidence around the safety of conventional DMARDs and TNFi at the time of live attenuated virus vaccination is reassuring, the total number of RMD patients who have been studied is small, and the Voting Panel conditionally recommended against administering live attenuated virus vaccines to patients receiving those agents as well as",
            "<p>d. In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical.</p>\n\n<p>e. the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</p>\n\n<h1>When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero</h1>\n\n<p>|Antenatal drug exposure in second or third trimester|Within the first 6 months of life|After 6 months of life|\n|---|---|---|\n|TNF inhibitor|Give rotavirus vaccine| |\n|Rituximab|Do not give rotavirus vaccine|Give rotavirus vaccine|</p>",
            "<p>§ For medications with &gt;1 dosing interval approved by the Food and Drug Administration, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks, although it can be dosed every 1 or every 2 weeks).</p>\n\n<p>¶ In children with autoinﬂammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic disease-modifying antirheumatic drugs are held is very high, shorter hold times can be considered if live attenuated vaccination is critical.</p>\n\n<h1>The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efﬁcacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</h1>\n\n<h1>Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*</h1>",
            "in the rare instances in which patients with active disease may not be able to receive conventional immunosuppressive therapy (e.g., sepsis or pregnancy), IVIG can be used as a short-term intervention until conventional remission induction therapies can be used Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events. AAV is associated with an increased risk of venous thrombotic events, including both deep vein thromboses and pulmonary emboli Recommendations and ungraded position statements for EGPA EGPA is characterized by diverse features, including asthma/ allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. As these clinical features can potentially have differing responses to treatment, the management approach is typically based on a patient's disease features and severity. The recommendations presented here focus primarily on the use of immunosuppressive medications to",
            "and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks). d In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero"
        ]
    },
    {
        "pregunta": "15. What role do bDMARDs (biologic DMARDs) play in modifying vaccine response or safety profiles?",
        "respuesta": "Los fármacos biológicos modificadores de la enfermedad (bDMARDs) tienen un impacto relevante en la modificación de la respuesta inmunitaria a las vacunas en pacientes con enfermedades reumáticas musculoesqueléticas (RMD). \n\nSegún la información disponible:  \n\n- Los bDMARDs pueden reducir la inmunogenicidad de las vacunas, es decir, pueden disminuir la capacidad del organismo para generar una respuesta protectora adecuada tras la vacunación.  \n- A pesar de ello, la mayoría de las vacunas no vivas atenuadas son seguras para administrarse en pacientes bajo tratamiento con bDMARDs, sin necesidad de suspender estos medicamentos para la vacunación, salvo excepciones específicas (como rituximab y metotrexato, que sí requieren manejo particular alrededor del momento vacunal).  \n- La seguridad del uso de vacunas en pacientes tratados con bDMARDs es generalmente favorable, con un perfil de reacciones adversas aceptable y bajo riesgo de activación o exacerbación de la enfermedad subyacente.  \n- Se recomienda no administrar vacunas vivas atenuadas en pacientes bajo bDMARDs debido al riesgo potencial de infección causada por la vacuna.  \n\nEn resumen, los bDMARDs pueden modificar la respuesta inmunitaria a las vacunas reduciendo su eficacia parcial, pero no contraindican la vacunación con vacunas no vivas; el perfil de seguridad de las vacunas es adecuado en pacientes bajo bDMARDs, siempre con las debidas precauciones y manejo según el tipo de tratamiento inmunosupresor.",
        "contexto": [
            "the efficacy and durability of response to all vaccines across all age groups; 2) safety of primary and booster live attenuated virus vaccination in children taking methotrexate and/or biologic DMARDs; 3) assessment of the immunogenicity, reactogenicity, and disease flares following standard-dose, high-dose, and adjuvanted influenza vaccination, recombinant VZV vaccination, and primary and booster COVID-19 vaccination in RMD patients taking immunosuppressive medication; and 4) RCTs to test the safety and efficacy of holding DMARDs around the time of vaccination.  † The terms 'moderate', 'low', and 'very low' are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) definitions for quality of evidence. Moderate quality means that \"further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.\" Low quality means that \"further research is very likely to have an important impact on our",
            "should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the most commonly used bDMARDs in children Risk factors for poor prognosis and disease activity measures Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions. Use of validated disease activity measures is conditionally recommended",
            "<ul>\n<li>RA = rheumatoid arthritis; DMARDs = disease-modifying antirheumatic drugs; ACR = American College of Rheumatology; FDA = Food and Drug Administration; csDMARDs = conventional DMARDs; bDMARDs = biologic DMARDs; TNF = tumor necrosis factor; IL-6 = interleukin-6; tsDMARDs = targeted synthetic DMARDs.</li>\n</ul>\n\n<p>† Anakinra was not included due to infrequent use for patients with RA.</p>\n\n<h1>Table 2. Disease-modifying antirheumatic drugs (DMARDs) initiation*</h1>",
            "<ul>\n<li>MMR = measles, mumps, and rubella (vaccine); PPSV23 = pneumococcal polysaccharide vaccine; PCV13 = pneumococcal conjugate vaccine; csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; IVIG = intravenous immunoglobulin; IBD = inflammatory bowel disease; bDMARDs = biologic DMARDs; TNF = tumor necrosis factor; IL-6R = interleukin-6 receptor; BLyS = B lymphocyte stimulator; tsDMARDs = targeted synthetic DMARDs; CNS = central nervous system; anti-GBM = anti–glomerular basement membrane (disease).</li>\n</ul>\n\n<p>† COVID-19 vaccines were not included in this guideline because of the fast-changing face of the pandemic and related literature.</p>\n\n<p>‡ The recently approved pneumococcal vaccines, PCV15 and PCV20, were not included in the evidence review but are discussed in the text with reference to current Centers for Disease Control and Prevention guidelines.</p>\n\n<h1>Table 2. Glossary of terms</h1>",
            "<ul>\n<li>DMARDs = biologic disease-modifying antirheumatic drugs; RA = rheumatoid arthritis; TTT = treat-to- target; bDMARD = biologic DMARD; tsDMARD = targeted synthetic DMARD; NAFLD = nonalcoholic fatty liver disease.</li>\n</ul>"
        ]
    },
    {
        "pregunta": "16. Why is a 4-week hold period recommended before vaccination for patients on slow-acting conventional DMARDs?",
        "respuesta": "Se recomienda un período de suspensión de **4 semanas** antes de la vacunación con vacunas vivas atenuadas en pacientes que reciben fármacos modificadores de la enfermedad convencionales de acción lenta (como metotrexato, azatioprina, leflunomida, micofenolato mofetil, inhibidores de calcineurina, ciclofosfamida oral) debido a la **prolongada duración de acción** de estos medicamentos.  \n\nEste tiempo busca asegurar que la actividad inmunosupresora residual sea mínima para mejorar la respuesta a la vacuna y reducir riesgos, aunque se reconoce que **no existe evidencia directa que establezca el tiempo óptimo de suspensión**, por lo que se elige esta duración como medida precautoria basada en la farmacodinámica de los fármacos.",
        "contexto": [
            "<p>|Immunosuppressive medication|Hold before live-attenuated virus vaccine administration|Hold after live-attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoidsᵃ|4 weeks|4 weeks|\n|Methotrexate, azathioprineᵇ|4 weeks|4 weeks|\n|Leflunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL17, IL12/23, IL23, BAFF/BLyS inhibitors|1 dosing intervalᶜ|4 weeks|\n|IL6 pathway inhibitors|1 dosing intervalᵈ|4 weeks|\n|IL1 inhibitors| | |\n|Anakinra|1 dosing intervalᵈ|4 weeks|\n|Rilonacept|1 dosing intervalᵈ|4 weeks|\n|Canakinumab|1 dosing intervalᵈ|4 weeks|\n|Abatacept|1 dosing intervalᶜ|4 weeks|\n|Anifrolumab|1 dosing intervalᶜ|4 weeks|\n|Cyclophosphamide IV|1 dosing intervalᶜ|4 weeks|\n|Rituximab|6 months|4 weeks|\n|IVIGᵉ| | |\n|300-400 mg/kg|8 months|4 weeks|\n|1 gm/kg|10 months|4 weeks|\n|2 gm/kg|11 months|4 weeks|</p>",
            "and the Voting Panel conditionally recommended against administering live attenuated virus vaccines to patients receiving those agents as well as other forms of immunosuppression. For patients who do need to receive live attenuated vaccines, specific recommendations for holding immunosuppressive medications around the time of vaccination can be found in Table 5 For slow-acting conventional DMARDs, a prevaccination hold time of 4 weeks was chosen to reflect their prolonged duration of action. However, direct evidence for the optimal hold time is lacking. For most biologic DMARDs, a hold time of 1 dosing interval before live attenuated vaccine administration is recommended. The number of RMD patients who are taking immunosuppressive medications at the time that they need live attenuated virus vaccines is small. However, very young children, especially those with autoinflammatory disorders, may require biologic DMARDs before their primary vaccination series is complete. In these",
            "<p>§ For medications with &gt;1 dosing interval approved by the Food and Drug Administration, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks, although it can be dosed every 1 or every 2 weeks).</p>\n\n<p>¶ In children with autoinﬂammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic disease-modifying antirheumatic drugs are held is very high, shorter hold times can be considered if live attenuated vaccination is critical.</p>\n\n<h1>The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efﬁcacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</h1>\n\n<h1>Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*</h1>",
            "<p>| |Hold before live attenuated virus vaccine administration|Hold after live attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoids†|4 weeks|4 weeks|\n|Methotrexate, azathioprine‡|4 weeks|4 weeks|\n|Leﬂunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL-17, IL-12/23, IL-23, BAFF/BLyS inhibitors|1 dosing interval§|4 weeks|\n|IL-6 pathway inhibitors|1 dosing interval¶|4 weeks|\n|IL-1 inhibitors|1 dosing interval¶|4 weeks|\n|Anakinra|1 dosing interval¶|4 weeks|\n|Rilonacept|1 dosing interval¶|4 weeks|\n|Canakinumab|1 dosing interval¶|4 weeks|\n|Abatacept|1 dosing interval§|4 weeks|\n|Anifrolumab|1 dosing interval§|4 weeks|\n|Cyclophosphamide, intravenous|1 dosing interval§|4 weeks|\n|Rituximab|6 months|4 weeks|\n| <strong>IVIG#</strong>  |  |  |<br />\n| 300–400 mg/kg     | 8 months     |  4 weeks |\n|  1 gm/kg   |   10 months            | 4 weeks      |\n|2 gm/kg  |  11 months | 4 weeks  |</p>",
            "and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks). d In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero"
        ]
    },
    {
        "pregunta": "17. How should vaccination be approached in patients receiving prednisone doses between >10 mg and <20 mg daily?",
        "respuesta": "En pacientes con enfermedades reumáticas musculoesqueléticas (RMD) que reciben dosis de prednisona mayores a 10 mg y menores a 20 mg diarios, la guía **condicionalmente recomienda**:\n\n- **Administrar la vacuna antigripal** (influenza) sin demora.  \n- **Administrar las demás vacunas no vivas atenuadas** también, sin diferir la vacunación.\n\nEsto refleja que, aunque la inmunogenicidad pueda estar algo reducida en este rango de dosis, el beneficio de vacunar oportunamente prevalece sobre la preocupación por la respuesta inmune.  \n\nPor tanto, para prednisona entre >10 mg y <20 mg/día:  \n- **Vacunación de influenza: + Condicionalmente dar**  \n- **Otras vacunas no vivas atenuadas: + Condicionalmente dar**\n\nNo se recomienda posponer la vacunación en estas circunstancias.",
        "contexto": [
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>\n\n<p>**Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt; 20 mg daily.</p>\n\n<p>++ Strong Recommendation</p>\n\n<ul>\n<li>Conditional recommendation</li>\n</ul>\n\n<h1>Table 3. Immunosuppressive medication management at the time of live-attenuated virus vaccine administration</h1>",
            "non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally recommended. Most studies that have compared prednisone <10 mg daily to prednisone ≥10 mg daily found that the higher dosages did reduce influenza vaccine immunogenicity Given the importance of timely influenza vaccination, a conditional recommendation was made to administer influenza vaccination to patients receiving the equivalent of prednisone ≥20 mg daily. For vaccines other than for influenza, a conditional recommendation was made to delay vaccination until the dose is lower to maximize vaccine efficacy. It is understood, however,",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non–live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579                  |",
            "| <strong>For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "<p>† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>\n\n<h1>Table 4. Whether to give or defer non–live attenuated vaccinations that can be safely given to RMD patients taking immunosuppressive medication.</h1>\n\n<p>|                               | <strong>Influenza vaccination</strong>    | <strong>Other non–live attenuated vaccinations</strong> |\n|-------------------------------|------------------------------|--------------------------------------------|\n| <strong>Prednisone ≤10 mg daily<em></strong>   | ++ Give                         |  ++Give                                       |\n| <strong>Prednisone &gt;10 mg and &lt;20 mg</em></strong> | + Give                         | + Give                                       |\n| <strong>Prednisone ≥20 mg daily*</strong>   | + Give                         | + Defer†                                     |</p>"
        ]
    },
    {
        "pregunta": "18. How do the hold times differ for medications with more than one FDA-approved dosing interval?",
        "respuesta": "Para los medicamentos que tienen más de un intervalo de dosificación aprobado por la FDA (por ejemplo, adalimumab, que puede administrarse cada 1 o cada 2 semanas), la recomendación es **elegir el intervalo más largo** para el período de suspensión antes de la vacunación o procedimiento.\n\nEsto significa que, al planificar la suspensión para mejorar la respuesta a la vacunación o disminuir riesgos, se debe basar el tiempo en el **intervalo más prolongado aprobado** por la FDA, incluso si la frecuencia de dosificación usada es más corta en un paciente particular.\n\nPor ejemplo, para adalimumab subcutáneo, se recomienda suspenderlo por 2 semanas (el intervalo más largo aprobado), aunque algunos pacientes lo reciban cada semana.",
        "contexto": [
            "<p>§ For medications with &gt;1 dosing interval approved by the Food and Drug Administration, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks, although it can be dosed every 1 or every 2 weeks).</p>\n\n<p>¶ In children with autoinﬂammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic disease-modifying antirheumatic drugs are held is very high, shorter hold times can be considered if live attenuated vaccination is critical.</p>\n\n<h1>The recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efﬁcacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay.</h1>\n\n<h1>Table 6. When to administer live attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero*</h1>",
            "<p>| |Hold before live attenuated virus vaccine administration|Hold after live attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoids†|4 weeks|4 weeks|\n|Methotrexate, azathioprine‡|4 weeks|4 weeks|\n|Leﬂunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL-17, IL-12/23, IL-23, BAFF/BLyS inhibitors|1 dosing interval§|4 weeks|\n|IL-6 pathway inhibitors|1 dosing interval¶|4 weeks|\n|IL-1 inhibitors|1 dosing interval¶|4 weeks|\n|Anakinra|1 dosing interval¶|4 weeks|\n|Rilonacept|1 dosing interval¶|4 weeks|\n|Canakinumab|1 dosing interval¶|4 weeks|\n|Abatacept|1 dosing interval§|4 weeks|\n|Anifrolumab|1 dosing interval§|4 weeks|\n|Cyclophosphamide, intravenous|1 dosing interval§|4 weeks|\n|Rituximab|6 months|4 weeks|\n| <strong>IVIG#</strong>  |  |  |<br />\n| 300–400 mg/kg     | 8 months     |  4 weeks |\n|  1 gm/kg   |   10 months            | 4 weeks      |\n|2 gm/kg  |  11 months | 4 weeks  |</p>",
            "and the risk of a disease flare off immunosuppression is high. c for medications with more than one FDA-approved dosing interval, the longest interval should be chosen (e.g., hold subcutaneous adalimumab for 2 weeks although it can be dosed every 1 or every 2 weeks). d In children with autoinflammatory disorders or systemic juvenile idiopathic arthritis in whom the risk of disease flare if biologic DMARDs are held is very high, shorter hold times can be considered if live-attenuated vaccination is critical. e the recommendation to hold IVIG prior to vaccination is designed to enhance vaccine efficacy, not safety. In some situations, such as during a measles outbreak, earlier vaccination would be preferred over delay. When to administer live-attenuated rotavirus vaccination to infants exposed to immunosuppressive medications in utero",
            "<p>|Immunosuppressive medication|Hold before live-attenuated virus vaccine administration|Hold after live-attenuated virus vaccine administration|\n|---|---|---|\n|Glucocorticoidsᵃ|4 weeks|4 weeks|\n|Methotrexate, azathioprineᵇ|4 weeks|4 weeks|\n|Leflunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide|4 weeks|4 weeks|\n|JAK inhibitors|1 week|4 weeks|\n|TNF, IL17, IL12/23, IL23, BAFF/BLyS inhibitors|1 dosing intervalᶜ|4 weeks|\n|IL6 pathway inhibitors|1 dosing intervalᵈ|4 weeks|\n|IL1 inhibitors| | |\n|Anakinra|1 dosing intervalᵈ|4 weeks|\n|Rilonacept|1 dosing intervalᵈ|4 weeks|\n|Canakinumab|1 dosing intervalᵈ|4 weeks|\n|Abatacept|1 dosing intervalᶜ|4 weeks|\n|Anifrolumab|1 dosing intervalᶜ|4 weeks|\n|Cyclophosphamide IV|1 dosing intervalᶜ|4 weeks|\n|Rituximab|6 months|4 weeks|\n|IVIGᵉ| | |\n|300-400 mg/kg|8 months|4 weeks|\n|1 gm/kg|10 months|4 weeks|\n|2 gm/kg|11 months|4 weeks|</p>",
            "<h1>Table 2. MEDICATIONS TO WITHHOLD PRIOR TO SURGERY<em>*</em></h1>"
        ]
    },
    {
        "pregunta": "19. What does the guideline suggest about administering multiple vaccines on the same day to RMD patients?",
        "respuesta": "La guía sugiere que, en pacientes con enfermedades reumáticas musculoesqueléticas (RMD), la administración de **múltiples vacunas en el mismo día** está **condicionalmente recomendada** en lugar de administrar cada vacuna en días diferentes. \n\nEsta práctica está apoyada para evitar la pérdida de oportunidades de vacunación y es una rutina tanto en medicina pediátrica como adulta, además de estar avalada por el CDC. \n\nEn resumen, se favorece aplicar varias vacunas en una sola visita para maximizar la cobertura vacunal y minimizar omisiones en la inmunización de pacientes con RMD.",
        "contexto": [
            "discussed with the pregnant RMD patient prior to delivery. Specifically, the pregnant patient should be educated as to the fact that medications that cross the placenta may affect vaccination schedules for their infants. A copy of the current vaccine guideline summary ( https:// www.rheumatology.org/Portals/0/Files/Vaccinations-Guidance- Whether to give multiple vaccinations to patients with RMD on the same day. For patients with RMD, giving multiple vaccinations on the same day rather than giving each individual vaccination on a different day is conditionally recommended. Administering >1 vaccination on a single day is a routine practice in both pediatric and adult medicine that is supported by the CDC in order to avoid a missed vaccination opportunity A summary of the guideline recommendations, associated PICO questions, and level of evidence can be found in Table 7 DISCUSSION This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD",
            "| <strong>Whether to give multiple vaccinations to patients with RMD on the same day</strong>         |                                                  |                                                                                                                      |                          |</p>",
            "evidence can be found in Table 7 DISCUSSION This is the first guideline to address vaccination strategies across the entire adult and pediatric RMD spectrum. An underlying principle in this guideline is that patients should be vaccinated, and that missed vaccination opportunities should be avoided or minimized. This is particularly true regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no studies assessing the impact of holding medications around the time of vaccination, particularly for vaccines other than for influenza. Therefore, many of the",
            "Rosters of the Core Leadership Team, Literature Review Team, Voting Panel, and Patient Panel are included in Supplementary Appendix 4, available on the Arthritis Care & Research website at http:// onlinelibrary.wiley.com/doi/10.1002/acr.25045 The following guiding principles were used in this guideline: 1) indicated vaccinations should be given to patients whenever possible; 2) this guideline is complementary to recommendations from the ACIP RESULTS/RECOMMENDATIONS Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination For patients with RMD age ≥65 years and patients with RMD age >18 years and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. Any influenza vaccine is preferred over no influenza vaccine, and vaccination \"today\" is preferred over delay. Therefore, if high-dose or adjuvanted",
            "2022 American College of Rheumatology (ACR) Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases      D064A5AD64D848FEC553AA8136BD6112 10.1002/acr.25045  Conclusion: Application of these recommendations should take into consideration patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended. For patients with RMD aged >18 years who are"
        ]
    },
    {
        "pregunta": "20. What are the key differences between live attenuated and non-live vaccines regarding their use in immunocompromised patients?",
        "respuesta": "Las principales diferencias entre las **vacunas vivas atenuadas** y las **vacunas no vivas (inactivadas)** en cuanto a su uso en **pacientes inmunocomprometidos** son:\n\n1. **Seguridad y riesgo:**\n   - Las **vacunas vivas atenuadas** están **contraindicadas o recomendadas condicionalmente en contra** en pacientes inmunocomprometidos, incluidos aquellos que reciben medicamentos inmunosupresores como bDMARDs, tsDMARDs (inhibidores JAK), metotrexato o rituximab. Esto se debe al riesgo de infección causada por la vacuna, ya que el virus o bacteria atenuada puede replicarse y causar enfermedad en pacientes con sistema inmunitario debilitado.\n   - Las **vacunas no vivas** (inactivadas) son consideradas **seguras para administrar** en pacientes inmunocomprometidos, incluso cuando están en tratamiento con la mayoría de los inmunosupresores, sin necesidad de suspender la medicación en la mayoría de los casos (excepto situaciones específicas como metotrexato o rituximab, que pueden requerir manejo particular).\n\n2. **Eficacia y respuesta inmune:**\n   - La inmunogenicidad de las vacunas vivas atenuadas puede verse afectada por los tratamientos inmunosupresores, y además, existe riesgo de que la vacuna cause infección.\n   - Las vacunas no vivas no implican riesgo de infección por el agente vacunante y su eficacia puede mantenerse suficientemente, aunque algunos inmunosupresores pueden reducir la respuesta inmunitaria.\n\n3. **Interferencia por tratamientos concomitantes:**\n   - La **administración de inmunoglobulina intravenosa (IVIG)** puede interferir con la eficacia de las vacunas vivas atenuadas, disminuyendo su capacidad para inducir inmunidad, por lo que se recomienda suspender IVIG antes de dichas vacunas.\n   - No hay necesidad de suspender inmunosupresores como regla general para las vacunas no vivas.\n\n4. **Ejemplos de vacunas vivas atenuadas:**\n   - Vacuna influenza intranasal (vacuna viva atenuada)  \n   - Vacuna MMR (sarampión, paperas y rubéola)  \n   - Vacuna varicela  \n   - Vacuna zóster viva  \n   - Rotavirus  \n   - Vacuna antitifoidea oral  \n   - Vacuna de fiebre amarilla\n\n5. **Ejemplos de vacunas no vivas (inactivadas):**\n   - Vacuna contra la influenza estacional inactivada (no intranasal)  \n   - Vacunas neumocócicas (PPSV23, PCV13)  \n   - Vacunas contra Haemophilus influenzae tipo b  \n   - Vacunas hepatitis A y B  \n   - Vacuna virus del papiloma humano  \n   - Vacunas meningocócicas  \n   - Vacuna toxoide tetánico  \n   - Vacuna antitifoidea inyectable  \n   - Vacuna zóster subunidad (no viva)\n\n**En resumen:**  \n- **Vacunas vivas atenuadas**: riesgo de causar infección en pacientes inmunocomprometidos; se evitan o recomiendan condicionalmente en contra; requieren suspensión previa de algunos inmunosupresores y de IVIG para optimizar seguridad y eficacia.  \n- **Vacunas no vivas**: seguras en general para pacientes inmunocomprometidos, con poca o ninguna necesidad de suspender tratamientos; recomendadas para prevenir infecciones en esta población vulnerable.\n\nEsta diferencia fundamental determina la estrategia de vacunación en pacientes con enfermedades reumáticas bajo inmunosupresión.",
        "contexto": [
            "<p>| <strong>Immunosuppressive</strong>                                                                                                       | <strong>Non-Immunosuppressive</strong>                                                                                            | <strong>Non-live attenuated</strong>                                                                                                                                                                                                                  | <strong>Live attenuated</strong>                                                                                                                                                                  | <strong>Rheumatic and Musculoskeletal Disorders</strong>                                                 |",
            "<h1>Table 1. Medication management at the time of non-live attenuated vaccine administration</h1>",
            "<h1>Table 2. Glossary of terms</h1>\n\n<p>|Term|Definition|\n|---|---|\n|Adjuvant|An ingredient used in some vaccines that helps create a stronger immune response in patients receiving the vaccine|\n|Immunogenicity|The ability of a vaccine to elicit an immune response|\n|Reactogenicity|Typical symptoms (e.g., fever, sore arm, muscle aches) that occur shortly (days) after vaccine administration either at the site of vaccination or systemically|\n|Seroconversion|Development of antibodies to a pathogen, elicited by a vaccine (or infection), in the blood of an individual who previously did not have detectable antibodies|\n|Seroprotection|An antibody level capable of protecting against infection or disease|\n|Titer|Numerical value indicating the level of antibody against a particular pathogen|</p>\n\n<h1>Table 3. Medication management at the time of non–live attenuated vaccine administration</h1>",
            "patients developed vaccine-associated infection, and 7 of 17 patients experienced disease flares JAK inhibitors. Cutaneous vaccine-strain varicella infection developed in 1 of 55 RA patients given a single dose of the live attenuated VZV vaccine 2-3 weeks prior to tofacitinib initiation in the context of an RCT. Later testing demonstrated that the study participant lacked prevaccination immunity to VZV Intravenous immunoglobulin (IVIG). Antiviral antibodies contained in IVIG can interfere with replication of live attenuated vaccines and reduce their efficacy Specific recommendations for holding medications if live attenuated vaccines are given. Although the evidence around the safety of conventional DMARDs and TNFi at the time of live attenuated virus vaccination is reassuring, the total number of RMD patients who have been studied is small, and the Voting Panel conditionally recommended against administering live attenuated virus vaccines to patients receiving those agents as well as",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>\n\n<p>**Defer vaccination until glucocorticoids are tapered to the equivalent of prednisone &lt; 20 mg daily.</p>\n\n<p>++ Strong Recommendation</p>\n\n<ul>\n<li>Conditional recommendation</li>\n</ul>\n\n<h1>Table 3. Immunosuppressive medication management at the time of live-attenuated virus vaccine administration</h1>"
        ]
    }
]